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The allosteric inhibition of the lymphocyte function associated antigen-1/intercellullar adhe-
sion molecule (LFA-1/ICAM-1) interaction, by a class of small molecules, is characterized by
a battery of mass spectrometric techniques. Binding of hydantoins to the I domain of LFA-1 is
observed by size exclusion chromatography/mass spectrometry (SEC/MS) and by direct
electrospray ionization mass spectrometry (ESI/MS). A photoactive hydantoin analog specif-
ically labels an amino acid residue of LFA-1 I domain. Competition with this photoaffinity
labeling by a panel of inhibitors is correlated with their Kd’s for inhibition of the LFA-1/ICAM
interaction. Alterations to the tertiary structure of LFA-1 I domain, upon compound binding,
are inferred from perturbation in the ESI mass spectrum of the polypeptide’s charge state
distribution and by an altered level of nonspecific multimer formation. The results demon-
strate specific, stoichiometric, reversible binding of the hydantoins to LFA-1. They further
show correlation of this binding with activity and indicate alterations in the polypeptide’s
tertiary structure, on hydantoin binding, consistent with the proposed mechanism for
inhibition of the protein–protein interaction. (J Am Soc Mass Spectrom 2003, 14, 8–13) © 2003
American Society for Mass Spectrometry
The study of inhibition of a protein-protein inter-action by a small molecule is a particularly chal-lenging task. When putative inhibitors are iden-
tified via high throughput screening (HTS) technologies
it is essential to characterize the mechanism of their
inhibition so that inhibitors operating via various un-
desirable modes of action (for development of a thera-
peutic drug), such as nonspecific binding, irreversible
binding, etc. can be efficiently eliminated. These con-
cerns prompted the studies of the hydantoins’ mode of
action described herein. General and efficient means are
required to eliminate all but the most promising hits
from a HTS campaign (the BI screening library contains
several hundred thousand small molecules). It is also
useful to obtain an indication that binding will be
sufficient to produce the desired inhibitory effect.
LFA-1 is a member of the 2-integrin family of
proteins and plays a pivotal role in directing proinflam-
matory cells into sites of inflammation [1–4]. Antago-
nists of this protein have therapeutic potential for
several inflammatory and autoimmune diseases. The
hydantoin, BIRT377 (CMPD 12), is a potent antagonist
of LFA-1 [5]. The compound exerts its influence by
binding to a region on LFA-1 (I- or “inserted”-domain)
and preventing a conformational change necessary for
LFA-1 to bind to its ligands, the intercellular adhesion
molecules (ICAM’s) [6].
We have reported the elucidation of the ligand-
binding site of a novel class of antagonists of LFA-1. The
binding site was identified in the absence of cocrystal-
lization studies by docking the inhibitor into a known
crystal structure of the apo-protein. Photoaffinity label-
ing (PA) was combined with enzymatic digestion and
mass spectrometric analyses to identify the amino acid
residue where photo attachment occurred [7]. This
information was a critical component of the successful
modeling effort.
Several mass spectrometric techniques are available
for the study of the mode of action of small molecule
leads identified by high capacity screens. In general, the
MS based technologies have the advantage that only
small amounts of protein reagent are required. The
direct observation of the small molecule binding to the
complex or a portion of the complex is an important
tool. This is frequently accomplished by ESI/MS con-
ducted under nondenaturing conditions [8–14]. The
charge distribution of the electrospray spectrum con-
tains important information related to the preservation
of intramolecular bonds and tertiary structure [15, 16].
ESI/MS spectra have been employed to characterize
specific, multimeric protein structures [17–21].
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Two methods in which mass spectrometry is em-
ployed for detection in combination with other proce-
dures were employed in this work. The use of SEC to
separate the protein/small molecule complex from un-
bound small molecules is combined with LC/MS de-
tection of the small molecules that are subsequently
released from the denatured complex [20–23]. This
technique was employed to verify binding of the small
molecule to LFA-1 I domain. Photoaffinity labeling
allows a specific, noncovalent interaction to be “frozen”
by creation of a covalent bond. This is accomplished by
incubation of a photoreactive, benzophenone analog of
the small molecule with the polypeptide and subse-
quent irradiation [24, 25]. Tryptic digestion and LC/MS
analysis then determined the location and extent of
labeling. [7]. In this report, the PA procedure is ex-
panded to provide a semiquantitative monitoring of
competitive binding. This allowed a correlation with
the results obtained from methods which directly mea-
sured the inhibition of the protein–protein interaction
between LFA-1 and ICAM.
Experimental
SEC/MS
The I domain of LFA-1 (rCD11a I domain, construct
KLB14.2.1) was prepared as previously reported [7] at a
concentration of 32 M in 10 mM TRIS, at pH 8 with 5
mM MnCl2 and 5 mM -mercaptoethanol. Stock solu-
tions of CMP1, CMPD 2, and CMPD 4 were prepared as
75 M solutions in DMSO. 1 ul aliquots of the three
small molecule inhibitors were combined with a 20 l
aliquot of the I domain of LFA-1 or a corresponding
buffer blank. 10 l injections, of these solutions, were
made and directed to the SEC column for trapping
(from 24–48 s at 4°C) and subsequent RPHPLC/MS or
directly to RPHPLC/MS for determination of response
factors and retention times. The apparatus and switch-
ing valve arrangement is essentially similar to that
previously reported [22]. Competitive photoaffinity
was conducted as previously described [7].
Direct ESI
Recombinant LFA-1 I domain was prepared as previ-
ously described [7]. The preparation was dialyzed over-
night versus water to produce an aqueous solution 40
M in I domain. 20 l aliquots of this solution were
diluted with 2 l of 0.1 M NH4OAc at pH 7. Incubation
with aqueous solutions of the various small molecules
was performed by adding ca. 4 l of each in aqueous
solution, containing 2% DMSO. The final solutions were
thus ca. 30.7 M in I domain, 0.008M NH4OAc, 0.3%
DMSO. Putative inhibitors are present at about 1.1
times molar excess to I domain unless otherwise stated.
The samples were analyzed by direct infusion ESI/MS
into an AutoSpec OATOF mass spectrometer (Micro-
mass, Manchester, UK) at 5 l/min. The instrument
was scanned from m/z 5000–1000 at 8 s/decade. Scans
were averaged in Profile mode. The skimmer and cone
voltages gave optimum preservation of the noncovalent
attachment at 12 and 15V. The source temperature was
77 °C. The ratio of peak heights for the denatured
monomer/native monomer was calculated as the aver-
age height of the 15 to 17 charge states/height of 8
charge state. The ratio of native multimer/native mono-
mer was calculated as the summed area of the 9 and
8 charge states divided by the summed area of the
multimer peaks above m/z  3200. The response from
m/z  3000–3200 may contain both dimer and monomer
response and was therefore not used.
Results and Discussion
Observation of Small Molecule Binding by
SEC/MS
The binding of hydantoin inhibitors to LFA-1 I domain
was demonstrated by SEC combined with RP HPLC/
MS. In this method, small molecules are first incubated
with polypeptide target. Size exclusion chromatogra-
phy is then employed to rapidly separate the polypep-
tide target, along with any small molecules bound to
the target, from any unbound small molecules. The
early eluting portion of the chromatogram containing
the target and bound molecules is trapped. This
trapped fraction is subjected to RP HPLC/MS. This
serves to denature the target, thus releasing the previ-
ously bound small molecules.
CMPD 1 is a hydantoin demonstrating low M
activity in the original HTS campaign which measured
the ability of small molecules to interrupt the LFA-1/
ICAM interaction. CMPD 2 has similar properties.
CMPD 4 is a small molecule with no activity in the
LFA/ICAM screen. Figure 1a shows the direct detection
of CMPD 1, CMPD 2, and CMPD 4 at 3.2 M. A similar
analysis of these components, again at 3.2 M, after
incubation with 32 M I domain and isolation of the
polypeptide peak by SEC is shown in Figure 1b.
Figure 1. Mass chromatograms for SEC/RPHPLCMS of three
hydantoins incubated with LFA-1 I domain. (a) is the control to
measure retention times and MS response. (b) shows the experi-
mental response after incubation, SEC, trapping, and RPHPLCMS.
Binding is thus observed for CMPD 1 and CMPD 2 and not
observed for CMPD 4. The broad peak observed at 12 min in (b)
is due to dissociated I domain.
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CMPD1 and CMPD2 showed strong binding, as ex-
pected, the inactive control showed no binding. The
additional closely eluting component in CMPD2 of the
same MW also bound, but was not further investigated.
This analysis confirms the binding of the original lead
compound and a related hydantoin to the I domain
portion of LFA. Note that detection requires the small
molecule to be released from the complex and thus
shows a reversible binding mode. A panel of 16 com-
pounds having Kd from 0.4 nM to 5 uM all showed
binding, while several inactive controls did not (data
not shown). The technique can distinguish between
those which bind and those that do not, but does not
exhibit a strong correlation with Kd, at least as imple-
mented here. In previous investigations of this tech-
nique [22], the most significant factor in the amount of
binding observed was found to be the relationship
between off rate and the time required for SEC isolation
of the complex.
Competitive Binding of Small Molecule Inhibitors
A photoaffinity probe analog (CMPD 5) was incubated
with LFA-1 I domain. The specific, noncovalent binding
of the inhibitor is “captured” by a subsequent irradia-
tion causing the benzophenone function to react with
nearby (2.5–3.1 Å reactive distance) extractable hydro-
gens of the target. The covalent bond thus formed is
stable to enzymatic digestion and LC/MS procedures
[24]. The attachment occurs at Pro281 in the tryptic
peptide FASKPASEFVK (residues 277–287) derived
from I domain. To demonstrate a correlation between
this specific binding of inhibitor and its ability to
interrupt the LFA-1/ICAM interaction the following
procedure was developed. LC/MS monitored the 2
charge state of the unlabeled peptide at m/z 605 and the
2 charge state of the peptide labeled by CMPD5 at m/z
973. The percentage response of this peptide undergo-
ing photoattachment under optimized conditions
(6.5%) was established. Several inhibitors were tested
for competition. Protection is calculated as a relative
reduction in percentage response of the labeled/unla-
beled peptide for each inhibitor. Approximately equal
amounts of photoprobe and inhibitor were employed at
about 10-fold molar excess to the LFA I domain.




Where Pr is the calculated fraction of
protection, R973 and R605 are the inte-
grated responses for the M  2H2 ions
of the labeled and unlabeled peptide
when incubated with a potential inhibitor
(ihbx) or without inhibitor (cont).
The level of protection for competitive binding to I
domain can be compared with Kd values determined
from the same set of compounds in the binding assay
which measures the ability of these inhibitors to inter-
rupt the binding of LFA-1 to ICAM-1 [5]. The inhibitor
Kd’s range from 50 nM to 10 M. A plot of Kd’s for
inhibition of LFA-1/ICAM binding versus protection of
Idomain PA labeling produced a slope of 1.17 and a r2
of 0.94 (see Figure 2). All data points were used to
calculate r2. This correlation demonstrates that binding
to the specific site identified on the I domain is directly
responsible for the interruption of ICAM-1/LFA-1
binding. CMPD 5 has a Kd of 460 nM in the LFA-1/
ICAM binding assay [5]. That assay has a good deal of
uncertainty, typically a factor of 2 to 3. It is also likely
that some of CMPD 5 is consumed in side reactions
during the irradiation making its effective concentra-
tion lower and increasing the level of protection.
Direct Observation of Inhibitor Binding to LFA-1 I
Domain
Direct ESI was employed to analyze I domain after
incubation with CMPD 6 and other inhibitors, at neutral
pH in ammonium acetate buffer. Low “skimmer volt-
age” and ESI source temperature were employed to
minimize fragmentation of the noncovalently bound
inhibitors. Most of the ion current was contained in the
9 and 8 charge states. LFA-1 has a metal binding
site, which is important for its function [26]. The protein
preparation contained manganese and this remained
bound after the dialysis. The binding of Mn and the
ligand are shown to be noncompetitive consistent with
the results of PA and modeling [7]. This observation is,
of course, only made after the experiment so it was
important to maintain Mn bound to the I domain. This
somewhat restricted our ability to perform desalting of
Figure 2. Correlation between inhibition of LFA-1/ICAM bind-
ing and protection from photoaffinity labeling of LFA-1 I domain
by several hydantoins. x  not used in calculation of the line.
Several weak binding inhibitors that did not protect LFA-1 I
domain from PA labeling are off-scale and thus not shown.
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the protein. In practice this did not prevent us from
accurately calculating the molecular weight of the
bound small molecule or observing a 1:1 stoichiometry.
Figure 3 shows an expansion of the m/z region contain-
ing the 8 charge state. Ions formed from I domain
without CMPD 6 (with and without Mn) were ob-
served. A more abundant pair of ions formed from I
domain with bound CMPD 6 (again with and without
Mn) was also observed. Only one molecule of inhibitor
binding was observed, even with molar excess of the
inhibitors. This is evidence for the specificity of the
binding. A panel of 12 compounds having Kd‘s from 1
to 0.01 M was analyzed in a similar manner. Eleven
showed binding. The ratio of bound to unbound peaks
varied from compound to compound, but did not corre-
late with Kd. Since all were present at levels significantly
above their Kd, it may be pointed out that their ability to
survive ESI without fragmentation did not correlate with
Kd. This is consistent with the observation that these Kd’s
are largely dependent on hydrophobic interactions. The
strength of hydrophobic interactions often does not corre-
late with ESI stability, in contrast to ionic and hydrogen-
bonding interactions that often show a strong correlation
with ESI stability [27].
Features of the ESI Spectrum Indicate
Conformational Change on Small
Molecule Binding
The charge state distribution in an electrospray spec-
trum has been shown to correlate with tertiary protein
structure [10–12, 17]. Mass spectra acquired under
“nondenaturing” conditions have fewer charges as ter-
tiary folding covers the polypeptide’s basic residues.
The spectra often have a narrow distribution of charge
states consistent with a single, dominant tertiary struc-
ture. Observation of a multi-modal distribution is evi-
dence for the presence of more than one structure. In
this study the spectrum of I domain was dominated by
ions of 9 and 8 charge states (see Figure 4 a and b).
This is consistent with a single predominant tertiary
conformation. This distribution shifts toward the 8
charge state on small molecule binding. This is consis-
tent with either an alteration of tertiary structure
and/or covering of a protonation site by the inhibitor. A
second broader distribution, of lower abundance, from
22 to 13 charge states was also observed. This
distribution is similar to that obtained by ESI under
denaturing conditions. The relative abundance of these
two conformations was found to vary with small mol-
ecule binding. Figure 5 shows the variation of peak
heights, in each distribution, observed on addition of
CMPD 6. The drastic reduction of response from dena-
tured species indicates that a different and stronger
conformation is formed on compound binding. This
conclusion is valid regardless of whether the denatur-
ation occurs in solution or during the ESI process.
Another set of charge distributions was observed in
the ESI spectra due to formation of multimers of the I
domain (this is also shown in Figure 5). Multimeric
species were observed in the m/z range 3000–5000. The
formation of these species was suppressed on com-
pound binding. This also suggests an alteration of
tertiary structure. Presumably, compound binding pro-
duces a more rigid structure without the flexibility
Figure 3. Direct ESI (nondenaturing conditions) of LFA-1 I
domain incubated with CMPD 6, expansion of 8 charge state
around m/z 2700. Calculated molecular weights are shown for
identified species.
Figure 4. Alteration in ESI spectra of LFA1 I domain produced
by compound binding (above) control with no hydantoin, (below)
with Compound 6. M  monomer, D  dimer, T  trimer.
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required to participate in the nonspecific interactions
required for multimer formation. ESI Spectra acquired
with an inactive hydantoin analog (CMPD 3) did not
produce these alterations.
The interaction of LFA-1 with ICAM involves two
very large molecules with a large area of contact. In this
sense a small molecule should not be able to bind a
small pocket and block activity, analogous to blocking
the active site of a catalytic enzyme, for instance. The
observation of conformational change on compound
binding, by ESI MS, is consistent with a mechanism
involving the locking of LFA-1 into an inactive confor-
mation unable to bind ICAM.
Conclusion
Mass Spectrometric methods demonstrate that a spe-
cific mechanism of binding is responsible for the inhi-
bition of the LFA-1/ICAM-1 interaction by small mol-
ecule hydantoins. This reversible binding occurs at a
site located within the I domain of LFA-1. Conforma-
tional changes of the LFA-1 I domain are indicated, by
mass spectrometry, consistent with the ability of a small
molecule to prevent the binding of two large proteins
having a large surface of interaction. The sensitivity and
flexibility of the MS methods allowed important infor-
mation to be obtained rapidly and efficiently. This
supplied direction and impetus to the project, in gen-
eral, and in particular to characterization of the mode of
action of the hydantoin inhibitors.
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